These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 9519777

  • 1. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon.
    Oka T, Sastry KJ, Nehete P, Schapiro SJ, Guo JQ, Talpaz M, Arlinghaus RB.
    Leukemia; 1998 Feb; 12(2):155-63. PubMed ID: 9519777
    [Abstract] [Full Text] [Related]

  • 2. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon versus STI571 (IRIS) Study Group.
    N Engl J Med; 2003 Oct 09; 349(15):1423-32. PubMed ID: 14534335
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J, Alvarez MA, Torres A.
    Haematologica; 2000 Oct 09; 85(10):1072-82. PubMed ID: 11025600
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon alpha therapy?
    Brizard F, Chomel JC, Veinstein A, Rivet J, Giraud C, Kitzis A, Guilhot F, Brizard A.
    Leukemia; 1998 Jul 09; 12(7):1076-80. PubMed ID: 9665193
    [Abstract] [Full Text] [Related]

  • 16. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
    Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA.
    Blood; 2004 Feb 01; 103(3):1037-42. PubMed ID: 14504104
    [Abstract] [Full Text] [Related]

  • 17. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.
    Branford S, Hughes TP, Rudzki Z.
    Br J Haematol; 1999 Dec 01; 107(3):587-99. PubMed ID: 10583264
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.